Market Capitalization (Millions $) |
192 |
Shares
Outstanding (Millions) |
38 |
Employees |
- |
Revenues (TTM) (Millions $) |
13 |
Net Income (TTM) (Millions $) |
-55 |
Cash Flow (TTM) (Millions $) |
-19 |
Capital Exp. (TTM) (Millions $) |
12 |
Vaccitech Plc
Vaccitech Plc is a biopharmaceutical company that specializes in the development of vaccines for various infectious diseases, including viral infections, such as influenza and hepatitis B. The company was founded in 2016 as a spin-out from the University of Oxford's Jenner Institute, and it has since gained recognition for its innovative approach to vaccine development.
Vaccitech's proprietary technology platform, known as the chimpanzee adenovirus vector (ChAdOx) system, enables the delivery of vaccines that stimulate a strong immune response against specific pathogens. This platform has been used in the development of several vaccine candidates, including the COVID-19 vaccine developed in collaboration with AstraZeneca.
In addition to its COVID-19 vaccine, Vaccitech is actively involved in the development of vaccines for other infectious diseases, such as MERS (Middle East Respiratory Syndrome) and human papillomavirus (HPV). The company also collaborates with various partners, including academic institutions, pharmaceutical companies, and government agencies, to advance its vaccine pipeline and bring its products to market.
Vaccitech Plc went public in April 2021 through an initial public offering (IPO) on the Nasdaq stock exchange, raising approximately $168 million. The company continues to focus on advancing its vaccine candidates, expand its pipeline, and contribute to global efforts to combat infectious diseases.
Company Address: Unit 6-10, Zeus Building Rutherford Avenue Didcot 0
Company Phone Number: 1865 818 808 Stock Exchange / Ticker: NASDAQ VACC
VACC is expected to report next financial results on March 23, 2024. |
|
|